Results 211 to 220 of about 60,177 (254)

Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1

Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992
We have shown that the urokinase (UK) kringle domain contains a high-affinity plasminogen activator inhibitor-1 (PAI-1) binding site, responsible for the 10-fold faster complex formation between UK and PAI-1 than between PAI-1 and low-molecular-weight urokinase (LMWUK).
J, Mimuro, M, Kaneko, T, Murakami, M, Matsuda, Y, Sakata   +4 more
openaire   +2 more sources

Plasminogen Activators and Plasminogen Activator Inhibitor 1 in Urinary Tract Cancer

Urologia Internationalis, 2010
The plasminogen activation system is considered to play an important role in cancer growth and metastasis. Both plasminogen activators (PAs) and their fast-acting inhibitors are produced in tumor cells and their surrounding tissues. In order to clarify the influence of the existence of malignant tumor in urinary tract on the systemic fibrinolytic ...
H, Bashar, T, Urano, K, Fukuta, M H, Pietraszek, M, Hata, K, Suzuki, K, Kawabe, Y, Takada, A, Takada   +8 more
openaire   +2 more sources

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Stroke Patients

Stroke, 1996
Background and Purpose Abnormal endogenous fibrinolytic activity may be a risk factor for stroke. Since the possible variation of tissue-type plasminogen activator (TPA) antigen and plasminogen activator inhibitor-1 (PAI-1) antigen concentrations over time after stroke has been rarely studied, it was examined in plasma from ...
A, Lindgren, C, Lindoff, B, Norrving, B, Astedt, B B, Johansson   +4 more
openaire   +2 more sources

Plasminogen activator inhibitor type 1 deficiency

Haemophilia, 2008
Summary.  Plasminogen activator inhibitor type 1 (PAI‐1) is an important component of the coagulation system that down‐regulates fibrinolysis in the circulation. Reduced PAI‐1 levels may result in increased fibrinolysis and an associated bleeding diathesis. Clear documentation of PAI‐1 deficiency as a cause of a bleeding disorder has been rare.
R, Mehta, A D, Shapiro
openaire   +2 more sources

Plasminogen Activator Inhibitor-1

2008
Fibrinolysis, the dissolution of fibrin clots, is an integral component of the hemostatic system that involves the concerted action of a complex system of zymogens, activators, and inhibitors [1]. Plasmin, the primary protease of the fibrinolysic system, digests fibrin, thereby converting insoluble clot to soluble fibrin degradation products.
Daniel T. Eitzman, William P. Fay, David Ginsburg   +2 more
openaire   +1 more source

Plasminogen activator inhibitor‐1 and diabetic nephropathy

Nephrology, 2005
SUMMARY:  Diabetic nephropathy is characterized by excessive accumulation of extracellular matrix (ECM) in the kidney. Decreased ECM degradation as well as increased ECM synthesis plays an important role in ECM remodeling that favours tissue fibrosis. Plasminogen activator (PA)/plasmin/PA inhibitor (PAI) system is involved in ECM degradation and PAI‐1 ...
Hi Bahl, Lee, Hunjoo, Ha
openaire   +2 more sources

Plasminogen Activator Inhibitor-1 in Vascular Thrombosis

Current Drug Targets, 2007
Thrombotic complications of vascular disease constitute the leading cause of morbidity and mortality in much of the developed world. Current drug therapies available to treat the thrombotic component of arterial and venous vascular complications remain limited.
Randal J, Westrick, Daniel T, Eitzman
openaire   +2 more sources

Plasminogen Activator Inhibitor-1 Is the Primary Inhibitor of Tissue-Type Plasminogen Activator in Pregnancy Plasma

Thrombosis and Haemostasis, 1987
SummaryThe aim of the present work was to clarify to what extent plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2) contribute to the increase in plasma inhibition of tissue-type plasminogen activator (t-PA) observed during pregnancy.
M, Jørgensen, M, Philips, S, Thorsen, J, Selmer, J, Zeuthen   +4 more
openaire   +2 more sources

A model of the active form of plasminogen-activator-inhibitor-1

Fibrinolysis, 1994
A model of the reactive form of plasminogen activator inhibitor-1 (PAI-1) has been constructed using molecular graphics and starting from the known crystal structure of latent PAI-1. The residues P16 to P10', of which P16-P4 form strand 4 of the beta-sheet A (s4A) and P3-P10' form an extended loop in the latent form, have been removed and remodeled ...
K, Aertgeerts, H L, De Bondt, C, De Ranter, P J, Declerck   +3 more
openaire   +2 more sources

Plasminogen activator inhibitor 1 in thrombotic disease

Current Opinion in Hematology, 1996
Impaired fibrinolytic function, mainly due to an elevation of plasma plasminogen activator inhibitor 1 concentration, is a common finding in patients with thrombotic disease. In patients subjected to hip surgery, preoperatively increased levels of plasminogen activator inhibitor 1 seem to be predictive of postoperative deep venous thrombosis.
openaire   +2 more sources